BCWM
NBIX icon

Bartlett & Co Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Bartlett & Co Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5
Closed -$487 – 1025
2021
Q2 		$487 Hold
5
– – ﹤0.01% 1027
2021
Q1 		$486 Hold
5
– – ﹤0.01% 1053
2020
Q4 		$479 Buy
+5
New +$483 ﹤0.01% 1155

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Bartlett & Co Wealth Management's NBIX Position: Q3 2021 in Review

Bartlett & Co Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q3 2021, closing a stake of 5 shares — an estimated $487 sold.

Bartlett & Co Wealth Management first reported a position in NBIX in Q4 2020 and held it in 3 quarters. The position peaked at $487 in Q2 2021. 395 funds tracked by Wall St. Rank hold NBIX as of Q3 2021.

  • Bartlett & Co Wealth Management reported no remaining Neurocrine Biosciences position as of Q3 2021 after selling out during the quarter.
  • Bartlett & Co Wealth Management sold 5 Neurocrine Biosciences shares in Q3 2021, an estimated $487.
  • Bartlett & Co Wealth Management first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 3 quarters.
  • Bartlett & Co Wealth Management's Neurocrine Biosciences position peaked at $487 in Q2 2021.
  • 395 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2021.

Based on Bartlett & Co Wealth Management's 13F filing for Q3 2021, filed 14 Feb 2024.